[go: up one dir, main page]

WO2010025505A1 - Analgésie par administration transmuqueuse - Google Patents

Analgésie par administration transmuqueuse Download PDF

Info

Publication number
WO2010025505A1
WO2010025505A1 PCT/AU2009/001143 AU2009001143W WO2010025505A1 WO 2010025505 A1 WO2010025505 A1 WO 2010025505A1 AU 2009001143 W AU2009001143 W AU 2009001143W WO 2010025505 A1 WO2010025505 A1 WO 2010025505A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
administration
administered
analgesia
transmucosal administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2009/001143
Other languages
English (en)
Inventor
Alexander James Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phebra Pty Ltd
Original Assignee
Phebra Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008904595A external-priority patent/AU2008904595A0/en
Application filed by Phebra Pty Ltd filed Critical Phebra Pty Ltd
Publication of WO2010025505A1 publication Critical patent/WO2010025505A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the invention described herein relates generally to anesthesia and analgesia.
  • the invention is directed to transmucosal administration of halogenated ethers for the treatment of pain, although the scope of the invention is not necessarily limited thereto.
  • Anaesthetic agents are generally administered intravenously or by inhalation into the lungs.
  • Anaesthetics used as analgesics are generally administered by inhalation into the lungs.
  • Australian Patent Application No. 2002362844 discloses administration of vaporized halogenated ethers by inhalation into the lungs for conscious sedation.
  • WO 2007/033400 discloses a method of treating pain comprising administering an effective dose of methoxyfiurane via an inhaler means into the lungs.
  • Administration of these agents intravenously or by inhalation into the lungs can be disadvantageous as intravenous administration is difficult in emergency situations outside of a hospital setting, and inhalation administration into the lungs requires active participation by the patient. The latter two routes can also lead to addiction to these agents. Therefore, there would be an advantage if it were possible to provide a route of administration of anaesthetics for analgesia, which may overcome at least some of the above-mentioned disadvantages or provide a useful or commercial choice.
  • the invention provides compositions of anaesthetics for transmucosal administration with unexpected advantages over the administration routes disclosed in the prior art.
  • the invention provides a composition comprising a solution of at least one volatile anaesthetic, wherein the composition is administered transmucosally for treating pain.
  • the invention provides a method of treating pain in a subject, the method comprising transmucosal administration of a composition to the subject, the composition comprising a solution of at least one volatile anaesthetic.
  • transmucosal administration includes intranasal administration and intrabuccal administration, where the drug is administered directly into the nasal cavity or buccal cavity with no administration to the lungs.
  • the composition comprises any appropriate anaesthetic.
  • the composition comprises one or more halogenated ether anaesthetics, including but not limited to sevofiurane, methoxyflurane, isoflurane, enflurane and desflurane.
  • the concentration of anaesthetic alone or as a mixture of anaesthetics in the composition can be any practicable concentration but is preferably from 1% to 100% of the composition.
  • the composition can be included in a device for transmucosal administration wherein the device is configured for a single dose or multiple dose administration.
  • the composition intended for multiple dose administration can include a preservative such as benzyl alcohol, LiquaPar® Oil (ISP Corporation), benzalkonium chloride, EDTA, benzethonium chloride, chlorobutanol, parabens and phenoxyethanol.
  • the preservative is LiquaPar® Oil, parabens, benzyl alcohol or benzalkonium chloride.
  • the composition can further comprise a fragrance component, such as an ester or artificial scent.
  • a fragrance component such as an ester or artificial scent.
  • the transmucosal administration of the composition can be effected in any practicable manner which limits the administration to preferably the nasal or buccal cavity, including by swab, droplets, spray or aerosol.
  • the composition is preferably administered by spray, from a suitable spray device, ensuring application to the nasal or buccal cavity only.
  • the device can be of any appropriate configuration, and is preferably a device which delivers a spray volume of between 1 ⁇ l and 1 ml per actuation of the device.
  • An example of such a device is a Valois® VP7 pump, or the Valois FreepodTM system.
  • composition can be packed and stored in any practicable container, including but not limited to glass vial Type 1 clear or amber glass of volume between 1 mL and 20OmL.
  • the invention therefore provides a composition for the treatment of pain comprising an anaesthetic for intranasal delivery, which overcomes many disadvantages of current administration regimes for analgesics as discussed below.
  • Formulations of the invention are made in the following manner. All examples have a finished volume of 1OmL.
  • composition is packaged in a glass vial of Type 1 clear or amber glass of volume from 0.1 milliliter up to 100 milliliters of the type typically used for an injection pharmaceutical.
  • composition may also be packaged in a single use device of the type manufactured by Valois SAS or equivalent such as the Valois MonodoseTM or DolphinTM.
  • a single use device of the type manufactured by Valois SAS or equivalent such as the Valois MonodoseTM or DolphinTM.
  • volume of a single-use container is between 0.1 and 2 milliliters
  • Transmucosal administration of halogenated ethers is particularly suited to rapid relief of emergency pain, treatment and management. Transmucosal administration also allows for administration of the drug to an incapacitated patient, without risk of subsequent addiction to the drug.
  • Sevoflurane in a Valois® VP7 spray pump was also administered buccally. Onset of analgesia was rapid (less than one minute) and analgesia lasted more than 20 minutes. Both rapid onset and retention of effect are important in emergency settings.
  • the invention provides an improved administration route for anaesthetic agents used for analgesia.
  • the invention provides a method of administration, transmucosally, of anaesthetics, particularly halogenated ethers, with enhanced drug delivery and drug uptake, which necessitates lower doses of the active and consequent lower incidence of side effects.
  • Optional inclusion of a preservative allows for provision of a multi-dose formulation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition comprenant une solution d'au moins un anesthésique volatil, la composition étant administrée par voie transmuqueuse pour le traitement d'une douleur, et un procédé de traitement d'une douleur comprenant l'administration transmuqueuse de la composition.
PCT/AU2009/001143 2008-09-04 2009-09-02 Analgésie par administration transmuqueuse Ceased WO2010025505A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008904595 2008-09-04
AU2008904595A AU2008904595A0 (en) 2008-09-04 Analgesia by Transmucosal Administration

Publications (1)

Publication Number Publication Date
WO2010025505A1 true WO2010025505A1 (fr) 2010-03-11

Family

ID=41796638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2009/001143 Ceased WO2010025505A1 (fr) 2008-09-04 2009-09-02 Analgésie par administration transmuqueuse

Country Status (2)

Country Link
TW (1) TW201010689A (fr)
WO (1) WO2010025505A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011866A1 (fr) 2015-07-20 2017-01-26 Medical Developments International Limited Dispositif inhalateur pour liquides à inhaler
WO2017011867A1 (fr) 2015-07-20 2017-01-26 Medical Developments International Limited Dispositif d'inhalateur pour liquides à inhaler
WO2017011865A1 (fr) 2015-07-20 2017-01-26 Medical Developments International Limited Dispositif d'inhalateur pour liquides à inhaler
US11571526B2 (en) 2016-09-06 2023-02-07 Medical Developments International Limited Inhaler device for inhalable liquids

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022116A1 (fr) * 2000-09-14 2002-03-21 Messer Griesheim Gmbh Agent anesthesique volatil au xenon
WO2007033400A1 (fr) * 2005-07-29 2007-03-29 Medical Developments International Limited Procédé de traitement de la douleur chez des patients
WO2008036858A2 (fr) * 2006-09-20 2008-03-27 The Board Of Regents Of The University Of Texas System procédé pour administrer des anesthésiants volatils pour une anesthésie locale et/ou le soulagement de la douleur
WO2009094460A2 (fr) * 2008-01-22 2009-07-30 Vapogenix, Inc. Compositions d'anesthésique volatil et procédés d'utilisation
WO2009094459A1 (fr) * 2008-01-22 2009-07-30 The Board Of Regents Of The University Of Texas System Compositions anesthésiques volatiles comprenant des solvants d'extraction pour une anesthésie régionale et/ou un soulagement de la douleur

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022116A1 (fr) * 2000-09-14 2002-03-21 Messer Griesheim Gmbh Agent anesthesique volatil au xenon
WO2007033400A1 (fr) * 2005-07-29 2007-03-29 Medical Developments International Limited Procédé de traitement de la douleur chez des patients
WO2008036858A2 (fr) * 2006-09-20 2008-03-27 The Board Of Regents Of The University Of Texas System procédé pour administrer des anesthésiants volatils pour une anesthésie locale et/ou le soulagement de la douleur
WO2009094460A2 (fr) * 2008-01-22 2009-07-30 Vapogenix, Inc. Compositions d'anesthésique volatil et procédés d'utilisation
WO2009094459A1 (fr) * 2008-01-22 2009-07-30 The Board Of Regents Of The University Of Texas System Compositions anesthésiques volatiles comprenant des solvants d'extraction pour une anesthésie régionale et/ou un soulagement de la douleur

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Alternative Routes of Drug Administration", PEDIATRICS., vol. 100, no. 1, 1997, pages 143 - 152 *
STANLEY, TH.: "Anesthesia for the 21st Century", BUMC PROCEEDINGS., vol. 13, 2000, pages 7 - 10 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011866A1 (fr) 2015-07-20 2017-01-26 Medical Developments International Limited Dispositif inhalateur pour liquides à inhaler
WO2017011867A1 (fr) 2015-07-20 2017-01-26 Medical Developments International Limited Dispositif d'inhalateur pour liquides à inhaler
WO2017011865A1 (fr) 2015-07-20 2017-01-26 Medical Developments International Limited Dispositif d'inhalateur pour liquides à inhaler
US11672925B2 (en) 2015-07-20 2023-06-13 Medical Developments International Limited Inhaler device for inhalable liquids
US11571526B2 (en) 2016-09-06 2023-02-07 Medical Developments International Limited Inhaler device for inhalable liquids

Also Published As

Publication number Publication date
TW201010689A (en) 2010-03-16

Similar Documents

Publication Publication Date Title
Eger et al. Clinical and economic factors important to anaesthetic choice for day-case surgery
Xue et al. Spray-as-you-go airway topical anesthesia in patients with a difficult airway: a randomized, double-blind comparison of 2% and 4% lidocaine
US10799466B2 (en) Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
EP1177793B1 (fr) Aérosol médicamenteux inhalable dans le traitement ou la prévention de la douleur
ES2450423T3 (es) Composición farmacéutica que comprende propofol
BRPI0418232A (pt) formulação inalante contendo éter sulfoalquìlico ciclodextrina e corticosteróide a partir de uma suspensão de dose unitária
BR0108730A (pt) Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados
RU2019100425A (ru) Новая доза и препаративная форма
US5496537A (en) Propofol hydrofluorocarbon propellant formulations
AU2007298814A1 (en) Galenic form for the trans-mucosal delivery of active ingredients
MXPA04002500A (es) Composiciones para el tratamiento de resfriado comun.
CN101678112A (zh) 用于递送治疗剂的方法和组合物
Zeppetella Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain.
Muyldermans et al. Partial nephrogenic diabetes insipidus in a burned patient receiving sevoflurane sedation with an anesthetic conserving device—a case report
WO2010025505A1 (fr) Analgésie par administration transmuqueuse
KR102060160B1 (ko) 혈관통을 개선한 로쿠로늄 제제 및 그 제조 방법 및 상기 로쿠로늄 제제를 사용한 혈관통의 억제·완화 방법
Fleischmann et al. Onset time, recovery duration, and drug cost with four different methods of inducing general anesthesia
JP2019516797A5 (fr)
RU2018143564A (ru) Карбоновая кислота, предназначенная для лечения/предупреждения заложенности носа
TW201002368A (en) Unit dose formulations of ketorolac for intranasal administration
JP3350678B2 (ja) 口腔用エアゾール製品
WO2009070829A1 (fr) Compositions de fentanyle à base d'huile, non aqueuses, pour une administration par voie transmucosale
JP2005187404A (ja) 粘膜外用噴霧組成物、点鼻剤及び口腔・咽喉疾患用剤
CN107137502A (zh) 一种鱼腥草雾化吸入用溶液制剂及其制备方法
WO2021198316A1 (fr) Composés, compositions et dispositifs destinés à être utilisés dans la prévention ou le traitement d'infections à coronavirus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09810916

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09810916

Country of ref document: EP

Kind code of ref document: A1